Pharmaceutical Technology

MARCH 1, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Drug Development Diabetes 40

Pharmaceutical Technology

FEBRUARY 26, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Immunization 40

Immunization Immunity Pharmaceutical Companies Pharmaceutical Companies 40

Pharmaceutical Technology

FEBRUARY 26, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Immunization 40

Immunization Immunity Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

MARCH 10, 2022

Biologics product development has increased steadily over the past decade, with the volume of business forecast to double by 2030. Driven by advancements in technology, these complex therapeutics have already made waves in life sciences, providing revolutionary treatment options in oncology, immune conditions and rare diseases.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Packaging Immunization 98

pharmaphorum

APRIL 28, 2022

For pharmaceutical companies, rare diseases present many challenges. AstraZeneca’s Alexion, which recently announced the building of a new rare disease development hub in Barcelona, is focused mostly on disorders of the complement system, a component of the immune system. How big pharma tackles rare diseases.

Immunization 59

Immunization Immunity Pharmaceutical Companies Pharmaceutical Companies 59

PharmaShots

MARCH 6, 2023

Traditionally patients were viewed by pharmaceutical companies as simply users of our products, nowadays they are considered partners working towards a collective goal. As a result of this progression, our industry developed the notion of patient-centricity.

Drug Development 40

Drug Development Immunization Immunity Pharmaceutical Companies 40

European Pharmaceutical Review

NOVEMBER 9, 2023

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

Drug Development 115

Drug Development Immunization Immunity Pharmaceutical Companies 115

Pharma Marketing Network

MAY 11, 2025

According to a recent analysis on Pharma Marketing Network , portfolio managers are advising caution in the Asia-Pacific pharmaceutical sector until regulatory clarity and new pricing structures stabilize. Though these companies operate on longer timelines and more complex supply chains, they arent immune. Is the U.S.

Drug Pricing 59

Drug Pricing Biosimilars Communication Immunization 59

European Pharmaceutical Review

APRIL 10, 2024

While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Notably, from one donor to another, significant variations exist.

Immunization 95

Immunization Immunity Chemotherapy Diabetes 95

pharmaphorum

OCTOBER 12, 2022

“We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says. Del Bourgo sees Debiopharm’s pharmaceutical industry expertise as an asset to the start-up as it expands its partnerships with new and international customers. “In

Drug Development 105

Drug Development Immunization Immunity Vaccines 105

Pharmacy Times

JUNE 23, 2025

CMS is issuing unique J-codes for 505(b)(2) drugs, classifying them as sole-source products if not therapeutically equivalent. This pathway reduces submission denial risk, accelerates drug development, and offers potential market exclusivity for up to 7 years.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Dosage Hospitals 26

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccines 64

Vaccines Drug Development Pharmaceutical Companies Pharmaceutical Companies 64

pharmaphorum

NOVEMBER 2, 2020

Predicting protein structures would typically be a time-consuming process, but now scientists can use technology to better analyse viruses, thus helping in the search for a vaccine that can trigger an immune response. This knowledge is critical in understanding how effective certain drugs might be in treating the virus.

Vaccines 132

Vaccines Drug Development Diabetes Immunization 132

PharmaShots

FEBRUARY 21, 2023

Other radiotherapies under the company's pipeline include Humalutin and Alpha37. Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases.

Dosage 56

Dosage Labelling Immunization Immunity 56

pharmaphorum

AUGUST 27, 2020

Over the past five to ten years US investors have focused on technology and internet companies, and relatively little on new biotech or pharmaceutical companies. The first is that the development of vaccines is utilising cutting edge technologies. Investment trends in the US influence investor appetite in the UK.

Vaccines 122

Vaccines Drug Pricing Compounding Immunization 122

Pharmaceutical Technology

AUGUST 26, 2008

It was once derided as the stuff of science fiction, but in recent years, biotechnology has emerged as an important growth area in pharmaceuticals. As understanding of biological systems has forged ahead, pharmaceutical companies have made increasing use of biotechnology in discovering and manufacturing new medicines.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Drug Development Vaccines 40

Pharmaceutical Technology

AUGUST 1, 2022

While the need for vaccines and drugs appeared more urgent than ever during the pandemic, it is possible that there will be more severe public health crises in years to come. AMR occurs when disease-causing bacteria become resistant or immune to the antibiotics used to treat them. million direct deaths in 2019 and an additional 4.95

Vaccines 93

Vaccines Pharmaceutical Companies Pharmaceutical Companies Chemotherapy 93

Pharmaceutical Technology

FEBRUARY 1, 2023

Pharmaceutical companies have been working on developing vaccines and other prophylactics for respiratory syncytial virus (RSV) since its discovery in 1956. Specific mutations can occur more rapidly when a virus is under immune selective pressure by prophylactic agents including mAbs and vaccines.

Vaccines 64

Vaccines Documentation Immunization Immunity 64

Pharmaceutical Technology

JUNE 25, 2025

RFK Jr has flip-flopped between endorsing and shunning the MMR vaccine , a shot that is proven to provide strong immunity against the disease. Historically, federal funding has been used to develop vaccines, as infectious disease markets are often not as lucrative as other indications.

Vaccines 115

Vaccines Hospitals Packaging Communication 115

BioPharma Dive

JUNE 11, 2025

billion buyout of Blueprint Medicines is the sector’s second-largest M&A deal this year and represents the highest value paid for an immune drug developer since April 2023. Track the deals that are happening here. Sanofi’s $9.1 Track the deals that are happening here. Sanofi’s $9.1

Drug Pricing 113

Drug Pricing Immunization Immunity Drug Development 113